Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
TSX Penny Stocks Under CA$60M Market Cap: Discovering Promising Opportunities

In This Article:

As the Canadian TSX index experiences a modest 3% rise amidst stabilizing yields and contained inflation, investors are increasingly looking for opportunities in smaller, potentially high-growth segments of the market. Penny stocks, while an older term, continue to capture attention due to their ability to represent smaller or newer companies with significant upside potential. By focusing on those with strong financials and clear growth paths, investors can uncover promising opportunities within this intriguing investment area.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Alvopetro Energy (TSXV:ALV)

CA$4.78

CA$175.48M

★★★★★★

Mandalay Resources (TSX:MND)

CA$4.73

CA$453.58M

★★★★★★

Findev (TSXV:FDI)

CA$0.52

CA$14.04M

★★★★★★

PetroTal (TSX:TAL)

CA$0.70

CA$641.48M

★★★★★★

NamSys (TSXV:CTZ)

CA$1.09

CA$31.16M

★★★★★★

East West Petroleum (TSXV:EW)

CA$0.045

CA$4.07M

★★★★★★

Orezone Gold (TSX:ORE)

CA$0.82

CA$379.19M

★★★★★☆

New Gold (TSX:NGD)

CA$3.89

CA$3.2B

★★★★★☆

Foraco International (TSX:FAR)

CA$1.92

CA$192.45M

★★★★★☆

DIRTT Environmental Solutions (TSX:DRT)

CA$1.04

CA$210.81M

★★★★☆☆

Click here to see the full list of 938 stocks from our TSX Penny Stocks screener.

We'll examine a selection from our screener results.

InnoCan Pharma

Simply Wall St Financial Health Rating: ★★★★★★

Overview: InnoCan Pharma Corporation is a pharmaceutical technology company that develops drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients across the United States, Canada, Europe, and internationally, with a market cap of CA$66.73 million.

Operations: The company generates revenue primarily from online sales, amounting to $28.86 million.

Market Cap: CA$66.73M

InnoCan Pharma Corporation, with a market cap of CA$66.73 million, remains pre-revenue and unprofitable but has shown progress by reducing losses over the past five years. Its innovative LPT-CBD platform has recently gained traction with a patent in India and positive feedback from the FDA for chronic pain management applications. Despite high volatility and negative return on equity, InnoCan benefits from being debt-free and having sufficient short-term assets to cover liabilities. The company also maintains a cash runway for 1.5 years, supported by recent private placements totaling CAD 635,444.60 to bolster its financial position further.

CNSX:INNO Revenue & Expenses Breakdown as at Feb 2025
CNSX:INNO Revenue & Expenses Breakdown as at Feb 2025

Foraco International

Simply Wall St Financial Health Rating: ★★★★★☆